NEUTRALIZATION OF TUMOR NECROSIS FACTOR IN PRECLINICAL MODELS OF SEPSIS
- 1 December 2005
- journal article
- review article
- Published by Wolters Kluwer Health in Shock
- Vol. 24 (Supplement) , 107-119
- https://doi.org/10.1097/01.shk.0000191343.21228.78
Abstract
Tumor necrosis factor (TNFα), a cardinal early mediator of the innate host inflammatory response, has been an attractive target for therapeutic intervention in human sepsis. However, pooled data from 12 completed randomized controlled trials show only a very modest impact on mortality in a highly heterogeneous population of patients. To gain insight into the preclinical in vivo biology of TNFα that might aid in better identifying appropriate patient populations for therapeutic intervention, we undertook a systematic review of published reports of preclinical studies assessing the consequences of neutralization of TNFα in models of acute infection or inflammation. We identified 143 reports incorporating 484 unique experimental comparisons in seven different animal species. The effects of neutralization of TNFα in these were quite variable. Neutralization of TNFα was beneficial in endotoxemia, or after systemic challenge with gram-negative organisms, Staphylococcus aureus, or Group B streptococci. On the other hand, neutralization was detrimental in infections caused by Streptococcus pneumoniae, Candida spp., or intracellular pathogens such as Listeria and Mycobacterium tuberculosis, and in models of pneumonia. Treatment was more efficacious when delivered before infectious challenge, and the therapeutic signal increased as the baseline mortality in the placebo group increased. Evidence of neutralization of TNFα bioactivity, and of attenuation of inflammation, was typically accompanied by evidence of impairment of antimicrobial defenses. Multiple specific and nonspecific therapeutic strategies were identified. We conclude that the beneficial effects of TNF in systemic inflammation occur at the cost of impaired antimicrobial defenses, and that a better understanding of the consequences of neutralization of TNFα in vivo could aid in better defining optimal patient populations for therapeutic intervention.Keywords
This publication has 148 references indexed in Scilit:
- Effect of Deficiency of Tumor Necrosis Factor Alpha or Both of Its Receptors onStreptococcus pneumoniaeCentral Nervous System Infection and PeritonitisInfection and Immunity, 2001
- Effect of a matrix metalloproteinase inhibitor on host resistance againstListeria monocytogenesinfectionFEMS Immunology & Medical Microbiology, 2000
- Enhanced Sensitivity of Tumor Necrosis Factor/Lymphotoxin‐α–Deficient Mice toCryptococcus neoformansInfection despite Increased Levels of Nitrite/Nitrate, Interferon‐γ, and Interleukin‐12The Journal of Infectious Diseases, 1999
- Mice heterozygous for a deletion of the tumor necrosis factor‐α and lymphotoxin‐α genes: biological importance of a nonlinear response of tumor necrosis factor‐α to gene dosageEuropean Journal of Immunology, 1997
- Introducing Critical Appraisal to studies of animal models investigating novel therapies in sepsisCritical Care Medicine, 1996
- Failure of prophylactic and therapeutic use of a murine anti-tumor necrosis factor monoclonal antibody in Escherichia coli sepsis in the rabbitCritical Care Medicine, 1995
- Acute lung injury during bacterial or fungal sepsisMicroscopy Research and Technique, 1993
- Tumour necrosis factor alpha antibody protects against lethal meningococcaemiaMolecular Microbiology, 1992
- Pentoxifylline inhibits lipopolysaccharide-induced serum tumor necrosis factor and mortalityLife Sciences, 1989
- Production of tumour necrosis factor in Listeria monocytogenes-infected animalsInternational Journal of Immunopharmacology, 1985